Trial intelligence / Profile preview

Raltegravir + OBT in treatment-experienced HIV

NCT00293254Phase 3Completed

Sponsor
Merck & Co.
Start
Feb 2006
Primary completion
Oct 2007
Modality
Small Molecules
01

Overview

A Phase 3 trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Started Feb 2006; status: completed.

02

Drugs

raltegravir
03

Conditions

human immunodeficiency virus infection (HIV)

Beyond the preview

Go deeper on NCT00293254.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00293254.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call